Encapsulating peritoneal sclerosis in Japan

Peritoneal Dialysis International

Volumn 28, Issue SUPP. 3, 2008, Pages

  Maruyama, Yukio ^a   Nakayama, Masaaki ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Encapsulating peritoneal sclerosis

Indexed keywords

CORTICOSTEROID;

ABDOMINAL CAVITY INFLAMMATION; ABDOMINAL SURGERY; ASCITES; BACTERIAL PERITONITIS; BIOCOMPATIBILITY; CLINICAL FEATURE; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ENCAPSULATING PERITONEAL SCLEROSIS; GASTROINTESTINAL SYMPTOM; HUMAN; JAPAN; LONG TERM CARE; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION;

GLUCOCORTICOIDS; HUMANS; INCIDENCE; JAPAN; PERITONEAL DIALYSIS; PERITONEAL DISEASES; PERITONEUM; SCLEROSIS; SEVERITY OF ILLNESS INDEX;

EID: 48749083851     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Nomoto Y, Kawaguchi Y, Sakai S, Hirano H, Kubo H, Ohira S, et al. Sclerosing encapsulating peritonitis (SEP) in patients on continuous ambulatory peritoneal dialysis - definition, diagnosis and treatment recommendation, 1997 update (Japanese). J Jpn Soc Dial Ther 1998; 31:303-11.
2. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):543-55.
3. Nakayama M. The plasma leak-to-response hypothesis: a working hypothesis on the pathogenesis of encapsulating peritoneal sclerosis after long-term peritoneal dialysis treatment. Perit Dial Int 2005; 25(Suppl 4):S71-6.
4. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420-7.
5. Oulès R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3:66-9.
6. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am S Kidney Dis 2004; 44:729-37.
7. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. on behalf of the Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
8. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
9. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-9.
10. Nakamura S, Miyazaki S, Sakai S, Morita T, Hirasawa Y, Niwa T. Localization of imidazolone in the peritoneum of CAPD patients: a factor for a loss of ultrafiltration. Am J Kidney Dis 2001; 38(Suppl 1):S107-10.
11. Nakayama M, Yoshimura K, Maruyama Y, Numata M, Hosoya T, Izumi G. Possible involvement of cross-linking advanced glycation end products in long-term CAPD peritoneal degeneration. Nephrol Oral Transplant 2004; 19:1664-5.
12. Nakamura S, Tobita K, Tachikawa T, Akamatsu S, Ohno Y, Kan A, et al. Immunohistochemical detection of an AGE, a ligand for macrophage receptor, in peritoneum of CAPD patients. Kidney Int Suppl 2003; 84:S152-7.
13. Nakamura S, Niwa T. Advanced glycation end-products and peritoneal sclerosis. Semin Nephrol 2004; 24:502-5.
14. Numata M, Nakayama M, Hosoya T, Hoff CM, Holmes CJ, Schalling M, et al. Possible pathologic involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients. Clin Nephrol 2004; 62:455-60.
15. Hauglustaine D, van Meerbeek J, Monballyu J, Goddeeris P, Lauwerijns J, Michielsen P. Sclerosing peritonitis with mural bowel fibrosis in a patient on long-term CAPD. Clin Nephrol 1984; 22:158-62.
16. Kawanishi H, Kawaguchi Y. Prevalence and therapeutic outcome of sclerosing encapsulating peritonitis (EPS)-a multicenter study in Japan (Japanese). Jin To Toseki 2000; 49(Suppl):225-8.
17. Nakamoto H, Kawaguchi Y, Suzuki H. Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. Adv Perit Dial 2002; 18:119-23.
18. Nakayama M, Hasegawa T. Clinical effect of corticosteroid and peritoneal lavage on encapsulating peritoneal sclerosis (EPS) (Japanese). Fukumakutoseki 2004:83-7.
19. Kawanishi H, Moriishi M, Tsuchiya S. Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. Adv Perit Dial 2006; 22:60-4.
20. Yamamoto R, Otsuka Y, Nakayama M, Maruyama Y, Katoh N, Ikeda M, et al. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol 2005; 9:148-52.
21. Izumotani T, Ishimura E, Yamamoto T, Otoshi T, Okuno S, Inaba M, et al. Correlation between peritoneal mesothelial cell cytology and peritoneal histopathology with respect to prognosis in patients on continuous ambulatory peritoneal dialysis. Nephron 2001; 89:43-9.
22. Hirano H. Morphology of the peritoneal membrane of CAPD patients during exposure to dialysate-peritoneal fibrosis and peritoneal sclerosis (Japanese). J Jpn Soc Dial Ther 2004; 37:135-44.
23. Yamamoto T, Izumotani T, Okuno S, Yamakawa T. Cohort study for the prevention of encapsulating peritoneal sclerosis by peritoneal lavage after peritoneal dialysis withdrawal (Japanese). J Jpn Soc Dial Ther 2007; 40:491-500.